View Document Preview and Link Document Date: 2006-03-22 08:30:18 Open Document File Size: 1,09 MB Share Result on Facebook
City Bayesian / Frazer / / Company Modafinil Treatment Group / Sponsor Cephalon Inc. / RS-IV ADR AE / Placebo Treatment Group / Phoenix Data Systems / Cephalon Inc. / Pennsylvania 19355 USA Cephalon Inc. / / Country United States / / Event FDA Phase / Product Issues / Product Recall / / Facility Health Statistics National Institute of Mental Health / / MedicalCondition OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER / Clinically Important Rash / ADHD / Non-urticarial Rash / SCARs / AttentionDeficit Hyperactivity Disorder / Narcolepsy / severe cutaneous adverse reactions standard deviation standard error Stevens-Johnson Syndrome / WBC selective serotonin-reuptake inhibitor Social Skills Rating Scale shift work sleep disorder / Skin Rash / toxic epidermal necrolysis / Oppositional Defiant Disorder / minimum month maculopapular exanthema / open-label obstructive sleep apnea/hypopnea syndrome / AttentionDeficit/Hyperactivity Disorder / Disorder / Obstructive Sleep Apnea/Hypopnea Syndrome / Attention-Deficit Hyperactivity Disorder / Obstructive Sleep Apnea/ Hypopnea Syndrome / Rash / Mental Disorders / Psychosis/Mania / Attention-Deficit/Hyperactivity Disorder / / MusicGroup Pulse / Endpoint / Mania / Psychosis / / Organization Psychopharmacologic Drugs Advisory Committee / US Food and Drug Administration / FDA / National Center / National Institute of Mental Health / / Person DAT DB DBH / / Position General / / Product Modafinil / Table / SNAP25 / S-019 / / Technology pharmacokinetics / CGI / / SocialTag 
Cephalon, Inc. NDA[removed]S-019 ADHD Indication